OSTX 8-K: Amendment No.1 to Bylaws Dated Aug 15, 2025

Rhea-AI Filing Summary

OS Therapies Incorporated submitted a Form 8-K reporting an amendment to its amended and restated bylaws titled "Amendment No. 1 to the Amended and Restated Bylaws of OS Therapies Incorporated". The filing is dated August 15, 2025 and is signed by Paul A. Romness, MPH, President and Chief Executive Officer. The company’s common stock trades under the ticker OSTX on NYSE American.

The 8-K provides the title of the bylaw amendment but does not include the text or a summary of the changes in the excerpt provided, so no specific governance changes, clauses, or operational effects can be described from the available content.

8-K Event Classification

2 items: 5.03, 9.01

2 items

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false --12-31 0001795091 0001795091 2025-08-15 2025-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 15, 2025

OS THERAPIES INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware		001-42195		82-5118368
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

115 Pullman Crossing Road, Suite 103 Grasonville, Maryland		21638
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (410) 297-7793

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		OSTX		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

CURRENT REPORT ON FORM 8-K

OS Therapies Incorporated

August 15, 2025

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On August 15, 2025, the Board of Directors (the “Board”) of OS Therapies Incorporated (the “Company”) approved and adopted an amendment (the “Amendment”) to Section 3.10 of Article III of the Company’s Amended and Restated Bylaws (the “Bylaws”), effective as of such date, to change the quorum for the transaction of business at stockholder meetings to one-third of the voting power of the outstanding shares of stock of the Company entitled to vote on a matter at the meeting, present in person or represented by proxy. For purposes of the foregoing, where a separate vote by class or classes is required for any matter, the holders of one-third of the voting power of the outstanding shares of such class or classes, present in person or represented by proxy, shall constitute a quorum to take action with respect to that vote on that matter.

Except as specifically amended above, the Bylaws remain in full force and effect.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of Amendment No. 1 to the Amended and Restated Bylaws of the Company, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
3.1		Amendment No. 1 to the Amended and Restated Bylaws of OS Therapies Incorporated.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OS THERAPIES INCORPORATED
Dated: August 15, 2025	By:	/s/ Paul A. Romness, MPH
		Name:	Paul A. Romness, MPH
		Title:	President and Chief Executive Officer

2

FAQ

What did OS Therapies (OSTX) file in this 8-K?

The company filed an 8-K reporting "Amendment No. 1 to the Amended and Restated Bylaws" dated August 15, 2025.

Who signed the 8-K for OS Therapies (OSTX)?

The filing is signed by Paul A. Romness, MPH, President and Chief Executive Officer.

Does the provided 8-K excerpt describe the specific bylaw changes?

No. The excerpt lists the amendment title but does not include the text or a summary of the specific bylaw changes.

On which exchange does OS Therapies (OSTX) trade?

OS Therapies’ common stock trades on NYSE American under the ticker OSTX.

Is there financial or transaction detail included in this filing excerpt?

No. The excerpt contains no financial tables, transaction details, or earnings information.